Top-News
Pharmazeutika USA

Karyopharm Therapeutics News

Aktie
WKN:  A1W77U ISIN:  US48576U1060 US-Symbol:  KPTI
1,061 €
+0,0445 €
+4,38%
03.05.24 16:47:58
Handeln Depot/Watchlist
Aktienanzahl *
114,53 Mio.
Marktkapitalisierung *
115,49 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 28.11.2023

Karyopharm Therapeutics News

02.05.24 - PR Newswire
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024 PR Newswire
01.05.24 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
24.04.24 - PR Newswire
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting PR Newswire
01.04.24 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
06.03.24 - PR Newswire
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences PR Newswire
01.03.24 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
29.02.24 - PR Newswire
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress PR Newswire
22.02.24 - PR Newswire
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 PR Newswire
01.02.24 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.01.24 - PR Newswire
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives PR Newswire
03.01.24 - PR Newswire
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
02.01.24 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
10.12.23 - PR Newswire
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve ...
01.12.23 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.11.23 - PR Newswire
Karyopharm to Participate at Upcoming Investor Conferences
Karyopharm to Participate at Upcoming Investor Conferences PR Newswire
06.11.23 - PR Newswire
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-​Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-...
02.11.23 - PR Newswire
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH) PR Newswire
02.11.23 - PR Newswire
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress PR Newswire
30.10.23 - PR Newswire
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients ...
02.10.23 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Newssuche

Videos

newspaper
03.05.24 -13,45%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »